🔎 Trials Near Me

Home › Triple-Negative Breast Cancer › Louisiana

Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Louisiana

6 pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa mga site sa Louisiana.

Mga Lungsod sa Louisiana

Opisyal na teksto ng pag-aaral (English)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109), Alexandria
  • Louisiana State University Health Sciences Shreveport ( Site 0029), Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06393374

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Ochsner Clinic Foundation ( Site 0021), New Orleans
  • Louisiana State University Health Sciences Shreveport ( Site 0053), Shreveport
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06966700

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  • Mary Bird Perkins Cancer Center, Baton Rouge
  • University Medical Center - New Orleans, New Orleans
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05633654

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

  • LSU Health Sciences Center, Shreveport
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2025 · NCT06700070

CtDNA Based MRD Testing for NAC Monitoring in TNBC

  • Louisiana State University, New Orleans
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Kababaihan · Na-update Ene 7, 2025 · NCT06230185

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.